PDE5A and cancer: Therapeutic strategies (including anti-CXCL13 antibody) to block B cell recruitment have efficiently hindered cancer progression and prevented cancer-associated myofibroblasts (CAMF) activation by phosphodiesterase 5 (PDE5) inhibitors or by deleting CAMF along with blocking the TGF-β receptor kinase [87].